Praxis Precision Medicines (PRAX) Liabilities and Shareholders Equity (2019 - 2026)

Praxis Precision Medicines' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 205.01% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $3.2 billion (up 78.51% YoY), while the FY2025 annual figure was $937.9 million, up 94.14% from the prior year.
• Liabilities and Shareholders Equity was $1.5 billion for Q1 2026 at Praxis Precision Medicines, up from $937.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.5 billion in Q1 2026 to a low of $87.9 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $377.4 million across 5 years, with a median of $250.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity slumped 60.67% in 2022, then surged 449.31% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $115.1 million in 2022, then declined by 23.61% to $87.9 million in 2023, then soared by 449.31% to $483.1 million in 2024, then jumped by 94.14% to $937.9 million in 2025, then jumped by 55.69% to $1.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.5 billion (Q1 2026), $937.9 million (Q4 2025), and $396.4 million (Q3 2025), per Business Quant data.